Tissue Regenix Group Plc (LSE:TRX) — Market Cap & Net Worth
Market Cap & Net Worth: Tissue Regenix Group Plc (TRX)
Tissue Regenix Group Plc (LSE:TRX) has a market capitalization of $628.37 (GBX5.16 Million) as of June 21, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31732 globally and #1315 in its home market, demonstrating a -99.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tissue Regenix Group Plc's stock price GBX0.07 by its total outstanding shares 71234507 (71.23 Million). Review TRX liabilities breakdown to assess the company's total debt and financial obligations.
Tissue Regenix Group Plc Market Cap History: 2015 to 2025
Tissue Regenix Group Plc's market capitalization history from 2015 to 2025. Data shows change from $13.22 Million to $628.37 (-62.66% CAGR).
Index Memberships
Tissue Regenix Group Plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$937.70 Million | 0.00% | #481 of 722 |
Weight: Tissue Regenix Group Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tissue Regenix Group Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tissue Regenix Group Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Tissue Regenix Group Plc's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $17.77 Million | $1.57 Million | -$10.68 Million | 11.29x | N/A |
| 2017 | $8.02 Million | $5.23 Million | -$9.22 Million | 1.53x | N/A |
| 2018 | $5.63 Million | $11.62 Million | -$8.19 Million | 0.48x | N/A |
| 2018 | $5.63 Million | $5.23 Million | -$9.22 Million | 1.08x | N/A |
| 2019 | $866.72K | $13.03 Million | -$6.97 Million | 0.07x | N/A |
| 2020 | $468.03K | $12.83 Million | -$9.71 Million | 0.04x | N/A |
| 2021 | $463.69K | $19.75 Million | -$4.79 Million | 0.02x | N/A |
| 2022 | $489.70K | $24.48 Million | -$2.69 Million | 0.02x | N/A |
| 2023 | $450.69K | $29.49 Million | -$1.71 Million | 0.02x | N/A |
| 2024 | $520.03K | $28.65 Million | -$713.00K | 0.02x | N/A |
Competitor Companies of TRX by Market Capitalization
Companies near Tissue Regenix Group Plc in the global market cap rankings as of June 21, 2026.
Key companies related to Tissue Regenix Group Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Tissue Regenix Group Plc Historical Marketcap From 2015 to 2025
Between 2015 and today, Tissue Regenix Group Plc's market cap moved from $13.22 Million to $ 628.37, with a yearly change of -62.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | GBX628.37 | -99.88% |
| 2024 | GBX520.03K | +15.38% |
| 2023 | GBX450.69K | -7.96% |
| 2022 | GBX489.70K | +5.61% |
| 2021 | GBX463.69K | -0.93% |
| 2020 | GBX468.03K | -46.00% |
| 2019 | GBX866.72K | -84.62% |
| 2018 | GBX5.63 Million | -29.73% |
| 2017 | GBX8.02 Million | -54.88% |
| 2016 | GBX17.77 Million | +34.43% |
| 2015 | GBX13.22 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Tissue Regenix Group Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $628.37 USD |
| MoneyControl | $628.37 USD |
| MarketWatch | $628.37 USD |
| marketcap.company | $628.37 USD |
| Reuters | $628.37 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tissue Regenix Group Plc
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal … Read more